Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients

References

1. Beck J., Nassal M. 2007; Hepatitis B virus replication. World J Gastroenterol 13:48–64[PubMed] [CrossRef]
   [Google Scholar]
2. Bozdayi G., Türkyilmaz A. R., Idilman R., Karatayli E., Rota S., Yurdaydin C., Bozdayi A. M. 2005; Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection. J Med Virol 76:476–481 [View Article][PubMed]
   [Google Scholar]
3. Chen R. Y., Edwards R., Shaw T., Colledge D., Delaney W. E. IV, Isom H., Bowden S., Desmond P., Locarnini S. A. 2003; Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37:27–35 [View Article][PubMed]
   [Google Scholar]
4. Cho E. Y., Choi C. S., Cho J. H., Kim H. C. 2001; Association between hepatitis B virus X gene mutations and clinical statusin patients with chronic hepatitis B infection. Gut Liver 5:70–76 [View Article]
   [Google Scholar]
5. Choi J. W., Ahn S. H., Park J. Y., Chang H. Y., Kim J. K., Baatarkhuu O., Kim Y., Han K. H., Chon C. Y. 2009; Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. J Med Virol 81:594–601 [View Article][PubMed]
   [Google Scholar]
6. D’Aurelio M., Vives-Bauza C., Davidson M. M., Manfredi G. 2010; Mitochondrial DNA background modifies the bioenergetics of NARP/MILS ATP6 mutant cells. Hum Mol Genet 19:374–386 [View Article][PubMed]
   [Google Scholar]
7. Eriksson N., Pachter L., Mitsuya Y., Rhee S. Y., Wang C., Gharizadeh B., Ronaghi M., Shafer R. W., Beerenwinkel N. 2008; Viral population estimation using pyrosequencing. PLOS Comput Biol 4:e1000074 [View Article][PubMed]
   [Google Scholar]
8. Fung J., Lai C. L., Seto W. K., Yuen M. F. 2011; Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 66:2715–2725 [View Article][PubMed]
   [Google Scholar]
9. Homs M., Buti M., Quer J., Jardí R., Schaper M., Tabernero D., Ortega I., Sanchez A., Esteban R., Rodriguez-Frias F. 2011; Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. Nucleic Acids Res 39:8457–8471 [View Article][PubMed]
   [Google Scholar]
10. Kidd-Ljunggren K., Miyakawa Y., Kidd A. H. 2002; Genetic variability in hepatitis B viruses. J Gen Virol 83:1267–1280[PubMed]
    [Google Scholar]
11. Koike K., Takada S. 1995; Biochemistry and functions of hepatitis B virus X protein. Intervirology 38:89–99[PubMed]
    [Google Scholar]
12. Livezey K. W., Negorev D., Simon D. 2000; Increased chromosomal alterations and micronuclei formation in human hepatoma HepG2 cells transfected with the hepatitis B virus HBX gene. Mutat Res 18:163–178[PubMed] [CrossRef]
    [Google Scholar]
13. Locarnini S. 2008; Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2:147–151 [View Article][PubMed]
    [Google Scholar]
14. Lok A. S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M. G., Pawlotsky J. M., Liaw Y. F., Mizokami M., Kuiken C. Hepatitis B Virus Drug Resistance Working Group 2007; Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46:254–265 [View Article][PubMed]
    [Google Scholar]
15. Mahtab M. A., Rahman S., Khan M., Karim F. 2008; Hepatitis B virus genotypes: an overview. Hepatobiliary Pancreat Dis Int 7:457–464[PubMed]
    [Google Scholar]
16. Margeridon-Thermet S., Shulman N. S., Ahmed A., Shahriar R., Liu T., Wang C., Holmes S. P., Babrzadeh F., Gharizadeh B. other authors 2009; Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 199:1275–1285 [View Article][PubMed]
    [Google Scholar]
17. Osborn M. K., Lok A. S. 2006; Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 57:1030–1034[PubMed] [CrossRef]
    [Google Scholar]
18. Papatheodoridis G. V., Hadziyannis S. J. 2001; Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 8:311–321[PubMed] [CrossRef]
    [Google Scholar]
19. Seeger C., Zoulim F., Mason S. W. 2007; Hepadnaviruses. In Fundamental Virology pp. 2977–3013 Edited by Fields B. N., Knipe D. M., Howley P. M. Philadelphia: Lipincott;
    [Google Scholar]
20. Sheldon J., Rodès B., Zoulim F., Bartholomeusz A., Soriano V. 2006; Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 13:427–434 [View Article][PubMed]
    [Google Scholar]
21. Smith T. F., Waterman M. S. 1981; Identification of common molecular subsequences. J Mol Biol 147:195–197 [View Article][PubMed]
    [Google Scholar]
22. Solmone M., Vincenti D., Prosperi M. C. F., Bruselles A., Ippolito G., Capobianchi M. R. 2009; Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 83:1718–1726 [View Article][PubMed]
    [Google Scholar]
23. Tacke F., Gehrke C., Luedde T., Heim A., Manns M. P., Trautwein C. 2004; Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. J Virol 78:8524–8535 [View Article][PubMed]
    [Google Scholar]
24. Zoulim F., Locarnini S. 2009; Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593–1608, e1–e2 [View Article][PubMed]
    [Google Scholar]